ACEi	angiotensin-converting enzyme inhibitors
ACR	albumin-to-creatinine ratio
ADA	American Diabetes Association
ANOVA	Analysis of variance
ARBs	angiotensin receptor blockers
BP	blood pressure
CKD	chronic kidney disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CVD	cardiovascular disease
DAPA-CKD	Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease
DBP	diastolic blood pressure
DKA	diabetic ketoacidosis
DM	diabetes mellitus
DN	diabetic nephropathy
eGFR	estimated glomerular filtration rate
EMPA-REG OUTCOME	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
ESRD	end-stage renal disease
HbA1c	hemoglobin A1c
IQR	interquartile range
JNC	Joint National Committee
K+	potassium
KDIGO	Kidney Disease: Improving Global Outcomes
KDOQI	National Kidney Foundation Kidney Disease Outcomes Quality Initiative
MAP	mean arterial pressure
MAU	microalbuminuria
MS	mean squares
NKF	National Kidney Foundation
NHBPEP	National High Blood Pressure Education Program
ONTARGET	Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
RAAS	renin–angiotensin–aldosterone system
RAASi	renin–angiotensin–aldosterone system inhibitors
Rx	prescription/treatment
SBP	systolic blood pressure
sCr	serum creatinine
SD	standard deviation
SGLT2i	sodium-glucose cotransporter-2 inhibitors
SGLT2i/ACEi	sodium-glucose cotransporter-2 inhibitor/angiotensin-converting enzyme inhibitor
SS	sum of squares
T1DM	type 1 diabetes mellitus
T2DM	type 2 diabetes mellitus
UAE	urinary albumin excretion
UTIs	urinary tract infections